What one share of Sangamo Therapeutics holds
We are a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases.
Sangamo Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-03-31; the balance sheet is as of 2026-03-31.
| Sales | $0.11 |
|---|---|
| Profit | −$0.38 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.28 |
| Cash and investments | $0.07 |
| Book value | −$0.05 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2009 | $0.53 | −$0.44 | $0.01 | −$0.15 | — | $1.70 |
| 2010 | $0.46 | −$0.55 | $0.02 | −$0.55 | — | $1.23 |
| 2011 | $0.20 | −$0.71 | $0.01 | −$0.52 | — | $1.52 |
| 2012 | $0.41 | −$0.42 | $0.01 | −$0.17 | — | $1.22 |
| 2013 | $0.43 | −$0.48 | $0.01 | −$0.36 | — | $1.96 |
| 2014 | $0.68 | −$0.39 | $0.01 | −$0.09 | — | $2.99 |
| 2015 | $0.57 | −$0.58 | $0.03 | −$0.52 | — | $2.74 |
| 2016 | $0.27 | −$1.02 | $0.01 | −$0.94 | — | $1.92 |
| 2017 | $0.47 | −$0.70 | $0.05 | $0.10 | — | $2.20 |
| 2018 | $0.87 | −$0.70 | $0.44 | −$0.07 | — | $3.59 |
| 2019 | $0.91 | −$0.85 | $0.18 | −$1.47 | — | $3.73 |
| 2020 | $0.88 | −$0.90 | $0.11 | $1.15 | — | $3.51 |
| 2021 | $0.77 | −$1.23 | $0.16 | −$1.77 | — | $2.57 |
| 2022 | $0.72 | −$1.25 | $0.13 | −$1.58 | — | $1.77 |
| 2023 | $1.01 | −$1.48 | $0.12 | −$1.41 | — | $0.47 |
| 2024 | $0.29 | −$0.49 | $0.00 | −$0.33 | — | $0.11 |
| 2025 | $0.14 | −$0.44 | $0.00 | −$0.35 | — | −$0.04 |
Common questions about Sangamo Therapeutics
How much does one share of Sangamo Therapeutics earn?
Over the last 12 months, Sangamo Therapeutics lost $0.38 for each share on $0.11 of sales.
Does Sangamo Therapeutics pay a dividend?
Sangamo Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Sangamo Therapeutics’s book value per share?
Sangamo Therapeutics’s book value is negative (−$0.05 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of March 31, 2026.
How much cash and debt does each share of Sangamo Therapeutics have?
Each share of Sangamo Therapeutics has $0.07 of cash and investments, as of March 31, 2026.
What is Sangamo Therapeutics’s free cash flow per share?
−$0.28 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Sangamo Therapeutics bought back shares?
Sangamo Therapeutics’s share count rose about 563% from 2009 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.